Table 6.
3-year economic attractiveness stability analysis
| CAD Group | 1 VD | 2 VD | 3 VD | LMD |
|---|---|---|---|---|
| Normal–mild CKD | ||||
| PCI vs. medical (%) | ||||
| Dominant | 0.20 | 1.00 | 6.00 | – |
| Cost-effectiveness | – | |||
| ≤$50,000/YOLS | 3.40 | 7.60 | 55.50 | – |
| ≤$150,000/YOLS | 46.60 | 43.80 | 28.00 | – |
| >$150,000/YOLS | 46.50 | 36.30 | 7.20 | – |
| Dominated | 3.30 | 11.30 | 3.30 | – |
| CABG vs. medical (%) | ||||
| Dominant | – | 0.10 | 3.00 | 0.70 |
| Cost-effectiveness | – | |||
| ≤$50,000/YOLS | – | 2.40 | 94.20 | 77.40 |
| ≤$150,000/YOLS | – | 21.40 | 2.80 | 19.80 |
| >$150,000/YOLS | – | 48.20 | 0.00 | 1.60 |
| Dominated | – | 27.90 | 0.00 | 0.50 |
| CABG vs. PCI (%) | ||||
| Dominant | – | 0.40 | 58.00 | – |
| Cost-effectiveness | – | – | ||
| ≤$50,000/YOLS | – | 3.00 | 25.90 | – |
| ≤$150,000/YOLS | – | 4.80 | 3.60 | – |
| >$150,000/YOLS | – | 8.20 | 2.20 | – |
| Dominated | – | 83.60 | 10.30 | – |
| Moderate–severe CKD | ||||
| PCI vs. medical (%) | ||||
| Dominant | 4.70 | 50.50 | 30.40 | – |
| Cost-effectiveness | – | |||
| ≤$50,000/YOLS | 26.40 | 14.80 | 17.10 | – |
| ≤$150,000/YOLS | 24.50 | 4.80 | 4.10 | – |
| >$150,000/YOLS | 13.50 | 2.70 | 2.80 | – |
| Dominated | 30.90 | 27.20 | 45.60 | – |
| CABG vs. medical (%) | ||||
| Dominant | – | 25.10 | 0.00 | 44.70 |
| Cost-effectiveness | – | |||
| ≤$50,000/YOLS | – | 63.50 | 12.80 | 47.50 |
| ≤$150,000/YOLS | – | 10.60 | 65.60 | 7.00 |
| >$150,000/YOLS | – | 0.50 | 20.60 | 0.70 |
| Dominated | – | 0.30 | 1.00 | 0.10 |
| CABG vs. PCI (%) | ||||
| Dominant | – | 1.70 | 0.0 | – |
| Cost-effective | – | – | ||
| ≤$50,000/YOLS | – | 81.90 | 11.00 | – |
| ≤$150,000/YOLS | – | 1.70 | 26.90 | – |
| >$150,000/YOLS | – | 13.50 | 59.50 | – |
| Dominated | – | 1.20 | 2.60 | – |
CAD Coronary artery disease, VD ventricular disease, LMD left main disease, CKD chronic kidney disease